The ARPA-H Moonshot Project, led by the US Advanced Research Projects Agency for Health (ARPA-H) in collaboration with Stanford University, aims to revolutionize therapeutic cloning by enabling the 3D printing of human organs. This initiative, known as the Health Enabling Advancements through Regenerative Tissue Printing (HEART) project, has received a substantial $26.3 million grant to develop a cutting-edge bioprinter integrated with a network of bioreactors. These bioreactors are designed to nurture specific types of cells, which will then be precisely ‘printed’ in their correct locations to construct target organs or tissues. The ultimate objective of the project is to successfully print a fully functional human heart and transplant it into a pig within a five-year timeframe.
The successful completion of the HEART project could pave the way for further advancements in therapeutic cloning, allowing for extensive testing on human subjects and the bioprinting of various organs such as lungs, kidneys, and more. While the principal investigator at Stanford University, Mark Skylar-Scott, anticipates that utilizing this technology on human patients may still be decades away, the life-saving potential it holds is immense. Recent data from the US Health Resources and Services Administration (HRSA) reveal a critical need for organ transplants, with over 42,000 transplants performed in the US in 2022, yet over a hundred-thousand patients await organ donations, leading to 17 deaths daily due to organ unavailability.
The HEART project’s innovative approach to therapeutic cloning underscores a significant leap forward in regenerative medicine, presenting a promising solution to the growing organ shortage crisis. By harnessing the power of bioprinting and advanced tissue engineering techniques, researchers aim to address the critical need for organ transplants and enhance patient outcomes. The integration of bioreactors into the bioprinting process enables the precise cultivation and deposition of cells, offering a customized approach to organ-specific therapeutic design that could revolutionize the field of transplantation medicine.
Key Takeaways:
– The HEART project, funded by ARPA-H and Stanford University, aims to advance therapeutic cloning for 3D printing human organs.
– The project involves developing a sophisticated bioprinter coupled with a network of bioreactors to cultivate specific cell types for organ construction.
– Successful completion of the project could lead to testing on human patients and the bioprinting of various organs beyond the heart.
– The integration of bioreactors in the bioprinting process offers a novel approach to organ-specific therapeutic design, potentially transforming organ transplantation practices.
Tags: bioreactor, bioprinting
Read more on hackaday.com